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Abstract
CONTEXT: One of the side-effects of chemotherapy is nephrotoxicity, whose incidence rate has reportedly been higher 
in pediatrics. Early diagnosis of renal dysfunction may decrease the morbidity in those with partial or complete remission 
by avoiding nephrotoxic agents and promoting regular follow-up. AIMS: We studied the frequency of renal dysfunction 
in pediatric patients whose therapy was completed regardless of the type of chemotherapy. SETTINGS AND DESIGN: 
Prospective cross sectional study in Hematoncology department of children’s hospital. MATERIALS AND METHODS: 
One hundred and eight pediatric cancer patients (44 females, 64 males), who were at least one year off therapy, enrolled 
in the study from 2003 to 2005. Demographic data, mean dosages of anticancer drugs, history of other nephrotoxic agents, 
nephrectomy, radiotherapy and acute renal failure were recorded. Fasting blood and urine samples were collected to calculate 
fractional excretion of magnesium, calcium, phosphate, urine protein to urine creatinine ratio, creatinine clearance (using 
Schwartz formula), urine analysis, urine osmolality and blood gas analysis. STATISTICAL ANALYSIS USED: T-test, Chi 
square and binary logistic regression were used to compare means, frequency and correlation respectively. P values < 
0.05 were considered signifi cant. RESULTS: Renal dysfunction was seen in 25.2% of cases. These abnormalities included 
hypercalciuria (7.2%), phosphaturia (13.5%), magnesuria (3.6%), glomerular fi ltration rate less than 90 ml/min (7.5%), 
metabolic acidosis (3%), metabolic alkalosis (10%), urinary concentration defect (19%), proteinuria (7.2%), glycosuria (2%), 
microscopic hematuria (4%), sterile pyuria (6%), and hypertension (8%). We found only Procarbazin as an independent 
variable of nephrotoxicity (P<0.05). CONCLUSIONS: Mild to moderate tubular dysfunction has been observed in the 
survivors of cancer disease. 




Although it improves the survival of children with 
cancer, chemotherapy is accompanied by late side-effects 
including organ dysfunction, second malignant neoplasm 
and adverse psychological sequelae. Tubular dysfunction, 
hypertension, renal failure, and bladder fibrosis 
have been reported as the predominant sequelae of 
radiotherapy, and Platinum, Ifosfamide, or Methotrexate 
chemotherapy. [1-6] Young age during treatment, 
higher cumulative doses, concurrent nephrotoxins 
administration, previous unilateral nephrectomy, and 
pre-existing renal impairment are listed as potential 
risk factors of nephrotoxicity.[7-16] We studied the 
frequency of nephrotoxicity in pediatric patients whose 
therapy was completed with no regard to the type of 
chemotherapy. 
Materials and Methods
One hundred and eight (64 male, 44 female) children 
aged two months to 15 years old at the time of 
diagnosis of neoplastic disease, in whom therapy 
was discontinued for at least one year, enrolled in 
a prospective cross sectional study in the oncology 
department of our hospital from 2003 to 2005. 
Informed consent was taken from patients or parents.
All information about demographic data, recurrence of 
disease, cumulative doses of anticancer drugs, tumor 
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lysis syndrome, history of nephrectomy (predominantly 
in Wilms’ tumor), radiotherapy, and other nephrotoxic 
antibiotics (including Aminoglycoside, Amphotericin 
B, Vancomycin, Acyclovir) were recorded. A complete 
physical examination was done and blood pressure was 
checked by standard sphygmomanometer. Blood pressure 
levels above 95% were defined as hypertension, using 
the Task Force normogram for age and height. Fasting 
blood and urine samples were sent to a laboratory to 
calculate the fractional excretion of calcium (FECa), 
magnesium (FEMg), phosphate (FEPh), urine protein to 
creatinine ratio (UP/UCr), and glomerular filtration rate 
(GFR) (using Schwartz formula). Urine analysis was 
performed to detect glycosuria, albuminuria, hematuria 
or pyuria; fasting urine specific gravity and urine 
osmolality was used to detect urinary concentration 
ability. Heparinized blood samples were taken for blood 
gases. Renal sonography was performed in all cases. 
Nephrotoxicity was defined by the presence of 
hypertension, hypercalciuria (FECa>5%), hypermagnesuria 
(FEMg>4%), phosphaturia (FEPh>25%), diluted urine 
(urine osmolality < 350 mosol/kg/H2O and specific 
gravity <1.015), acidosis (PH<7.35 and HCO3 <20) 
or alkalosis (PH>7.45 and HCO3 >26), proteinuria 
(UP/UCr >0.2 and positive dipstick for albumin), GFR 
<90 ml/min/m2, or glycosuria. We used T-test, Chi 
square and binary logistic regression to evaluate means, 
frequency and correlation. P values less than 0.05 were 
considered significant.
Results
The average age of patients was 12.9 years (± 
5.12 SD). Seventy-nine out of 108 patients had 
lymphoproliferative malignancies including leukemia 
(n=59) and lymphoma (n=20). Twenty-nine had 
solid tumors which consisted of Wilms’ (n=14), 
neuroblastoma (n=5), rhabdomyosarcoma (n=5), 
retinoblastoma (n=4) and yolk sac tumor (n=1). The 
mean length of therapy was 35.44 months (± 28.53 
SD). Treatment was discontinued for 52.48 months 
(± 40 SD) on average. Table 1 shows the type, mean 
dosage and the number of recipient of chemotherapy 
drugs. A few patients were treated by Ifosfamide or 
Platinum agents.
7.5% of patients had GFR less than 90 ml/min. 
Hypercalciuria and phosphaturia was observed in 7.2% 
and 13.5%, respectively. Magnesuria was detected 
in 3.6% of patients. Three percent of patients had 
metabolic acidosis and metabolic alkalosis was seen in 
10% of them.
Urine concentration defects were found in 19%. 
Proteinuria was detected in 7.2% of cases. Glycosuria 
was observed in 2%. Microscopic hematuria was found 
in 4%, and 6% of patients had sterile pyuria with 
negative urine culture. Hypertension was detected in 
8% of children. These renal dysfunctions were not 
correlated with the type of chemotherapy, sex, age of 
starting therapy, history of radiotherapy, nephrectomy, 
or administration of other nephrotoxic agents (Binary 
logistic regression, P>0.05).
25.2% of patients had more than one parameter of 
nephrotoxicity (13 of leukemia, seven of lymphoma, 
three of Wilms’ tumor, one of neuroblastoma, and two 
each of retinoblastoma and rhabdomyosarcoma). Using 
binary logistic regression analysis, we found a correlation 
only between nephrotoxicity and Procarbazin (odd ratio 
6.5, 95% Confidence Interval 1.12-37.7, P= 0.038). 
The type of chemotherapy, age at start of therapy, sex, 
nephrectomy, radiotherapy, and use of other nephrotoxic 
agents showed no correlation with nephrotoxicity 
(P >0.05). 
Discussion
We have shown that there is some degree of renal 
dysfunction in long-term follow-up of children with 
a history of chemotherapy. This abnormality was not 
correlated with the type of chemotherapeutic drugs 
or the neoplastic disease. A minority of patients were 
treated by Ifosfamide or Platinum agents but one-
third of cases generally had mild to moderate renal 
dysfunction.
A number of studies have been done on the long-
term outcome of renal function in survivors of 
childhood cancer. The majority of studies are concerned 
with nephrotoxicity in the acute phase of therapy 
especially induced by Ifosfamide, Cisplatin and 
Methotrexate. [3,5,7- 11,13-15,17]
Reduction of glomerular filtration rate has been reported 
after completion of therapy in 13% of patients.[2,3,5,18- 19] 
However, this reduction of GFR is subclinical or 
mild and is detected by elevation of serum levels of 
Cystatin C, serum creatinine, or by iGFR (chromium 
EDTA). [1,3- 4,17,19] High dose of Methotrexate, older age 
at the time of diagnosis, Wilms’ tumor, and triple 
therapy (surgery, chemotherapy and radiation) have been 
reported as risk factors.[17,18] None of these publications 
reported severe chronic renal failure and Koch 
Nogueira et al, observed that all long term survivors of 
osteosarcoma had GFR more than 80 ml/min despite 
receiving Ifosfamide, Cisplatin and Methotrexate.[3] A 
few of our patients showed mild reduction of GFR 
using the Schwartz formula; this effect was more 
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prominent in those who received nitrogen mustard. 
Serum Cystatin C is more sensitive in detecting GFR 
changes compared to serum creatinine. [1,17] Petal et 
al, showed that during chemotherapy iGFR had a 
value of 20% below GFR calculated by the Schwartz 
formula. [19] 
Tubular dysfunction is more persistent after 
chemotherapy has ended, and dysfunction of the organic 
anion transporter has been suggested as the probable 
mechanism.[2] In our study the urinary concentration 
defect was generally followed by phosphaturia and 
hypercalciuria. Detection of metabolic acid–base 
disorders, tubular proteinuria, glycosuria and diluted 
urine might suggest involvement of different parts 
of the nephron. No risk factor was detected for this 
tubular dysfunction but impaired urinary concentration 
was pronounced in those with solid tumors. Similar 
disorders have been reported in the literature.[1,3,5] Kveder 
et al, found normal fractional excretion of sodium, 
potassium, calcium and phosphate after 22 years follow-
up on average. The urinary N-acetyl-B-glucosaminidase 
(NAG) /creatinine ratio was highest in those patients 
who received triple therapy.[18] Proteinuria was more 
frequent in Kopecna’s study on survivors of acute 
lymphoblastic leukemia.[4] These reports may suggest 
proximal tubular dysfunction. Phosphaturia, calciuria, 
and metabolic acidosis made the children prone not 
only to osteoporosis but also to urolithiasis.[20-22] None 
of our patients had nephrolithiasis in renal sonography 
and another project is being conducted to evaluate bone 
densitometry in late survivors.
Hypertension has been reported as a late sequel of 
radiotherapy due to renal artery stenosis.[23] However, 
only 1.6% of all hypertensive patients in our group had 
a history of receiving radiotherapy. Acrolein, a metabolite 
by-product of Cyclophosphamide and Ifosfamide, may 
cause hemorrhagic cystitis and bladder fibrosis and 
increase the risk of developing bladder cancer.[24-26] Only 
4% of those who received Nitrosourea had microscopic 
hematuria. Because of an insufficient number of cases, 
we could not find any correlation between hematuria 
and those therapies. 
Few studies have been done about the overall incidence 
of nephrotoxicity in the survivors of chemotherapy. 
Putting all of the parameters together, one third of 
our patients showed mild to moderate nephrotoxicity 
independent of any risk factors. This finding shows the 
subclinical renal dysfunction in our survivors in whom 
its consequences must be determined.
In conclusion, mild to moderate tubular dysfunction has 
been observed in survivors of chemotherapy. Routine 
follow-up care of renal function is recommended.
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